Novavax up +6% As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK

Novavax (NASDAQ:NVAX) shares rose more than 6% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.

The trial had 29,960 participants across the U.S. and Mexico.

The vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said.

(NVAX to file for FDA approval in Q3)

[link to finance.yahoo.com (secure)]

Last Edited by DeploraVision ™ on 06/14/2021 12:01 PM